Ergoteles’s AnaptysBio ANAB Stock Holding History

Ergoteles’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18,224	Closed	-$565K	–	1220
2022 Q4	$565K	Buy	+18,224	New	+$515K	0.02%	657
2022 Q3	–	Sell	-13,963	Closed	-$283K	–	1527
2022 Q2	$283K	Sell	13,963 -5,392	-28%	-$119K	0.01%	1135
2022 Q1	$479K	Buy	+19,355	New	+$586K	0.02%	672
2021 Q3	–	Sell	-11,400	Closed	-$296K	–	1177
2021 Q2	$296K	Buy	+11,400	New	+$273K	0.01%	1071

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ergoteles's ANAB Position: Q1 2023 in Review

Ergoteles sold out of AnaptysBio (ANAB) in Q1 2023, closing a stake of 18,224 shares — an estimated $565K sold.

Ergoteles first reported a position in ANAB in Q2 2021 and held it in 4 quarters. The position peaked at $565K in Q4 2022. 113 funds tracked by Wall St. Rank hold ANAB as of Q1 2023.

Ergoteles reported no remaining AnaptysBio position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 18,224 AnaptysBio shares in Q1 2023, an estimated $565K.
Ergoteles first reported a position in AnaptysBio in Q2 2021 and held it in 4 quarters.
Ergoteles's AnaptysBio position peaked at $565K in Q4 2022.
113 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.